Sulfonylurea

Managing the risk of hypoglycemia remains a central challenge in diabetes care, even as newer therapies lower the rate of severe events. Although GLP-1 receptor agonists and SGLT2 inhibitors have reshaped treatment strategies, insulin and sulfonylureas are still widely used, especially among older adults and patients with chronic kidney disease …

New retrospective study results compare the two most primarily prescribed antidiabetic medication classes in addition to metformin to determine the impact on the incidence of CV events in patients with T2DM.

According to current research, linagliptin had a significantly lower risk of hypoglycemia and adverse events in geriatric patients with type 2 diabetes. 

Insulin is not recommended for COVID-19 patients with T2D due to increased mortality risk,

The most common treatment for T2D has been the metformin-sulfonylurea combo; how do SGLT-2 inhibitors compare in all-cause mortality risk?

A retrospective cohort analyzed the association of two commonly prescribed medications on heart failure outcomes in patients with reduced estimated glomerular filtration rate.

A closer look at the risk of major adverse events, severe hypoglycemia, and all-cause mortality for commonly used therapies in treating type 2 diabetes.

The CAROLINA and CARMELINA Trials offer further information regarding the CV safety of linagliptin and glimepiride among patients with T2DM, high CVD risk, and decreased renal function.  

After almost 50 years, is the age of sulfonylureas coming to an end?

A recent study found important effects on dementia in African American patients with type 2 diabetes